Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...

Shares of Merck MRK rose nearly 6% on Friday after the company announced that the EMA’s Committee for Medicinal Products for ...

Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

FDA Alerts on Risks From Merck’s Keytruda in Multiple Myeloma Following Halted Trials The US Food and Drug Administration (FDA) on Thursday released an alert and summary of findings from two halted ...

The FDA has approved a new injectable version of cancer drug Keytruda as Merck seeks to protect its market dominance. Here are five things to know: The approved shot is Keytruda Qlex, a widely used ...

On the Wednesday, April 15, 2026, episode of The Excerpt podcast: Prices for cutting-edge medical treatments can balloon in the U.S. health care system, leading to higher costs for the employer, ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

The US Food and Drug Administration (FDA) announced Tuesday that it has limited the use of Roche’s Tecentriq (atezolizumab) and Merck’s Keytruda (pembrolizumab) for patients with locally advanced or ...